Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group.

Document Type

Article

Publication Date

11-2022

Identifier

DOI: 10.1002/pbc.29937

Abstract

Infections cause substantial morbidity for children with acute lymphoblastic leukemia (ALL). Therefore, accurate characterization of infectious adverse events (AEs) reported on clinical trials is imperative to defining, comparing, and managing safety and toxicity. Here, we describe key processes implemented to improve reporting of infectious AEs on two active phase III Children's Oncology Group (COG) ALL trials. Processes include: (a) identifying infections as a targeted toxicity, (b) incorporation of infection-specific case report form questions, and (c) physician review of AEs with real-time data cleaning. Preliminary assessment of these processes suggests improved reporting, as well as opportunities for further improvement.

Journal Title

Pediatric blood & cancer

Volume

69

Issue

11

First Page

29937

Last Page

29937

MeSH Keywords

Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

acute lymphoblastic leukemia; adverse events; clinical trials; infections

Link to Full Text
Library Record

Share

COinS